These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 18472686

  • 1. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K.
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [Abstract] [Full Text] [Related]

  • 2. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R, Easom A, Juergensen P.
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [Abstract] [Full Text] [Related]

  • 3. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A.
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [Abstract] [Full Text] [Related]

  • 4. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C.
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [Abstract] [Full Text] [Related]

  • 5. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A.
    Semin Dial; 2009 Dec; 22(1):64-9. PubMed ID: 19175537
    [Abstract] [Full Text] [Related]

  • 6. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR.
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [Abstract] [Full Text] [Related]

  • 7. Assessing hyporesponse to Epoetin alfa: an algorithm approach: case study of the anemic patient.
    Wingard R.
    Nephrol Nurs J; 2000 Oct; 27(5):517-20. PubMed ID: 16649327
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R.
    Nephrol Nurs J; 2006 Oct; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC, Tian YC, Wu HH, Hsu PY, Huang JY, Chen YC, Fang JT, Yang CW.
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [Abstract] [Full Text] [Related]

  • 12. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M.
    Nephrol Nurs J; 2007 Mar; 34(5):527-31. PubMed ID: 18041455
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Refining the approach to IV iron use in hemodialysis patients: a post-DRIVE analysis.
    Sharma A, Vanderhalt K, Ryan KJ, Sclafani J.
    Nephrol News Issues; 2010 Apr; 24(4):22-6, 29-35. PubMed ID: 20458992
    [Abstract] [Full Text] [Related]

  • 15. A comprehensive vision for intravenous iron therapy.
    Coyne DW.
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [Abstract] [Full Text] [Related]

  • 16. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S, Cropper L, Mostafa S, Turner J, Bailey G, Pugh-Clarke K.
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [Abstract] [Full Text] [Related]

  • 17. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK, Hertello P.
    Nephrol Nurs J; 2005 Sep; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [Abstract] [Full Text] [Related]

  • 18. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M.
    Nephrol Nurs J; 2005 Sep; 32(4):423-6. PubMed ID: 16180783
    [Abstract] [Full Text] [Related]

  • 19. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K, Kairaitis L.
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [Abstract] [Full Text] [Related]

  • 20. IV iron therapy and anemia management in patients on hemodialysis: benefits of a revised CQI strategy.
    Bowe D.
    Nephrol Nurs J; 2008 Apr; 35(4):371-7, 394; quiz 378-9. PubMed ID: 18782999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.